Steven Pergam, MD, MPH, associate professor of the vaccine and infectious disease division at Fred Hutchinson Cancer Research Center in Seattle, WA, and infection prevention director at Seattle Cancer Care Alliance, co-led a National Comprehensive Cancer Network (NCCN) committee that issued recommendations on COVID-19 vaccination for patients with cancer. He received his first Moderna dose on December 29, 2020, and has been dispelling fear and spreading education about the vaccine.

When the U.S. Congress passed the FY 2021 funding bill at the end of 2020, it recommitted its dedication to cancer research by increasing the National Institutes of Health’s National Cancer Institute’s (NCI’s) budget by $120 million.

The ONS Board of Directors had a full agenda for its longer quarterly meeting on February 18–19, 2021. Among other work, it evaluated the results of the annual member satisfaction survey, discussed the fiscal health of the organization based on year-end financials, and continued the conversation on diversity, equity, and inclusion in nursing and cancer care. Details on the Board’s decisions in key areas follow, and ONS members can review the full meeting minutes at ons.org/board-minutes.  

Keeping up with what ONS is doing can be a challenge, given the communication overload we all experience. With so much information in our lives, personally and professionally, announcements can slip by without our noting them. Periodically I hear comments or feedback from members about something that has not changed or that did change—several years ago. To help you stay on top of all that’s happening, here are some details that you may have missed.

On March 31, 2021, the U.S. Food and Drug Administration (FDA) approved isatuximab-irfc (Sarclisa^®) in combination with carfilzomib and dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received one to three prior lines of therapy. 

Patients with higher muscle quality during treatment with PD-1/PD-L1 inhibitor monotherapy for non-small cell lung cancer (NSCLC) had higher overall response rates and longer progression-free survival than patients with lower-quality skeletal muscle, researchers reported in study findings published in Cancer Medicine.

The COVID-19 coronavirus pandemic has changed the world as we know it. The mortality rate is devasting, the economic impact is jarring, and no one can pinpoint any date for its end. But new vaccines offer a glimmer of hope—but only if the country can settle discussions about achieving adequate vaccination coverage and strategies to distribute and inoculate hundreds of millions of people.

In July 2020, the U.S. Food and Drug Administration approved decitabine and cedazuridine (Inqovi^®) tablets for the treatment of adults with myelodysplastic syndromes. 

On March 27, 2021, the U.S. Food and Drug Administration (FDA) approved idecabtagene vicleucel (Abecma), for the treatment of adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody. This is the first FDA-approved cell-based gene therapy for multiple myeloma. 

On March 25, 2021, the U.S. Food and Drug Administration shared Zydus Pharmaceuticals Inc.’s notice of its voluntary recall of four lots of acyclovir sodium injection 50 mg/ml, supplied in 10 ml and 20 ml vials, after receiving reports of crystallization in the product.